The HCPLive Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...
November 23rd 2024
With approval, acoramaidis becomes the first agent with a label specifying near-complete stabilization of TTR.
November 18th 2024
Elevating Care for PAH: Applying Recommended Management Approaches to Maximize Outcomes
View More
‘REEL’ Time Patient Counseling™: Navigating the Complex Journey of Diagnosing and Managing Fabry Disease
View More
Expert Illustrations & Commentaries™: Envisioning Novel Therapeutic Approaches to Managing ANCA-associated Vasculitis
View More
The 6-minute walk test in chronic heart failure
September 22nd 2008We examined the relationship between the 6-minute walk test and self-perceived changes in symptoms in 1077 elderly patients with chronic heart failure. We found that changes in 6-minute walk test distance were sensitive to changes in self-perceived symptoms of heart failure.
Sex-related differences in atrial fibrillation: Data from the RACE study
September 22nd 2008We evaluated the effects of rate control treatment versus sinus rhythm restoration and maintenance in patients with persistent atrial fibrillation in a substudy of the Rate Control Versus Electrical Cardioversion (RACE) trial. Rhythm control treatment was associated with greater cardiovascular morbidity and mortality in women. Because treatment did not improve quality of life in these patients, rate control may be considered as first-choice therapy for women.
Fundamentals of clinical research: Causal inference, surrogate measures, and intention to treat
The previous installment of this series on clinical research highlighted some important fundamentals in cohort studies and randomized controlled trials (RCTs). In this article, additional issues that are critical to the understanding of RCTs are discussed, including causal inference, the use of surrogate measures, and the principle of intention to treat (ITT).
It takes a gutsy person to sign up for a plenary session with that title. From the moment she took the podium, Grace Anne Dorney Koppel captivated a small audience with her moving story of her struggle with chronic obstructive pulmonary disease (COPD) and its many co-morbidities. With steely resolve, she challenged the physicians in the audience to step up their efforts to diagnose and treat a disease that currently affects more than 24 million Americans.
Undiagnosed diabetes mellitus in coronary artery bypass graft surgery
September 19th 2008We examined the prevalence and risks associated with undiagnosed diabetes mellitus among more than 7000 patients who had undergone coronary artery bypass graft surgery. At the perioperative and postoperative stages, patients with undiagnosed diabetes showed a significantly higher morbidity and mortality rate.
Untreated diabetes mellitus in coronary artery by pass graft surgery
Lauruschkat and colleagues entitled their article "Undiagnosed diabetes mellitus in coronary artery bypass graft surgery."
Elevated high-density lipoprotein cholesterol and carotid atherosclerosis
September 19th 2008We assessed the relationship between high-density lipoprotein (HDL) cholesterol level and carotid plaque progression in 1952 men and women with preexisting carotid atherosclerosis over a period of 7 years. The HDL cholesterol level was inversely related to plaque growth. The plaques that became more echogenic during follow-up had a lower growth rate compared with those that became more echolucent. These findings suggest that HDL cholesterol stabilizes plaques and counteracts their growth by reducing their lipid content and inflammation.
Initiating treatment for chronic heart failure
Standard congestive heart failure treatment begins with an angiotensin-converting enzyme (ACE) inhibitor to which a beta-blocker is added once the target dose of the ACE inhibitor has been reached. We compared morbidity and mortality between standard treatment and treatment using the reverse sequence, that is, the beta-blocker bisoprolol was given to patients first, followed by the ACE inhibitor enalapril. Results showed that both sequence strategies were safe and effective, with a survival trend in favor of the bisoprolol-first strategy.
The clinical ramifications of CIBIS III: Does the sequence of medication initiation really matter?
September 19th 2008The development of new and innovative mechanical and pharmacologic therapies for the broad spectrum of cardiovascular disease has led to dramatic changes in the makeup of clinical practice.
Obesity and cardiovascular risk in hypertensive patients with left ventricular hypertrophy
The observed relationship linking obesity, severity of hypertension, and increase in cardiovascular risk was traditionally thought to emanate from the increase in circulatory volume, persistently increased systemic resistance from obesity, and clustering of major cardiovascular risk factors (eg, hypercholesterolemia and diabetes mellitus) among obese patients.
Laboratory monitoring for spironolactone in congestive heart failure
September 19th 2008We evaluated how well patients taking spironolactone were monitored for hyperkalemia, as well as the association between spironolactone and hyperkalemia. Only two thirds of patients received testing for serum potassium and creatinine levels, and higher baseline serum creatinine levels predicted a high risk of hyperkalemia. These results indicate that appropriate patient selection and close monitoring are essential, especially for patients with renal impairment.
Spironolactone and hyperkalemia in congestive heart failure
In 1999 Pitt and colleagues published the results of the RALES trial, an important study showing that the addition of a relatively small dose of the aldosterone antagonist spironolactone to a regimen that included angiotensin-converting enzyme (ACE) inhibitors for patients with severe congestive heart failure (NYHA Class III-IV) had a striking benefit on mortality
Transcatheter occlusion of the left atrial appendage to prevent stroke in atrial fibrillation
September 19th 2008We conducted 2 feasibility studies to assess the performance and safety of the percutaneous left atrial appendage (LAA) transcatheter occlusion system for the prevention of stroke in high-risk patients with nonrheumatic atrial fibrillation. Results showed that percutaneous LAA occlusion can be performed using the device at acceptable risk. This procedure may be particularly useful for patients at increased risk of ischemic stroke with a contraindication to anticoagulation therapy.